# rheumatoid arthritis - gemini-3.6-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: DISEASE-STATE
- Tissue / sample source: synovial tissue
- Comparison or endpoint: rheumatoid arthritis versus normal control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: d868ce3efb219458b8d5ddb7b123eef3f2b718852ba0ede74f2a02e9181db293
- Response HTTP status: 200
- Prompt tokens: 44434
- Completion tokens: 32367
- Reasoning tokens: 6443
- Total tokens: 76801
- API requests reported: 3
- Elapsed seconds: 50.374
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 984.622
- Question handoff seconds: 999.892
- Final benchmark system: E2seq; file rank 4/5; original repeat 5; model vendor: Google Gemini

---
### Data-Quality Warning & Technical Context

An initial evaluation of the input statistical ledger reveals a highly unusual distribution: **all 100 top features are uniformly downregulated** in rheumatoid arthritis (RA) compared to normal control synovial tissue, accompanied by extreme statistical significance (P-values down to $3.17 \times 10^{-58}$ and FDRs down to $8.78 \times 10^{-54}$). 

This uniform downregulation across diverse biotypes (mRNAs, microRNAs, long non-coding RNAs, and small nucleolar/ribosomal RNAs) strongly indicates technical or sample-level confounding. The most probable causes include:
1. **Severe Cell-Composition Shifts**: Massive infiltration of immune cells (T cells, B cells, macrophages) into the RA synovium dilutes the relative abundance of resident stromal, lining, and extracellular transcripts.
2. **Platform or Sub-Selection Bias**: Selective inclusion of downregulated transcripts or technical saturation during normalization/differential testing.

In accordance with analytical standards, direct statistical evidence from this dataset is treated as exploratory, and **external statistical validation was not performed** on an independent cohort in this analysis. The following interpretation integrates direct input values with external pathway, interaction, and literature annotations to construct defensible functional hypotheses.

---

### 1. Overall Biological Interpretation

The provided transcriptomic dataset reflects a sweeping down-regulation of resident synovial structural integrity, cellular adhesion complexes, mucosal barrier components, epigenetic regulators, and metabolic homeostasis factors in RA synovial tissue compared to normal controls. 

Rather than isolated molecular lesions, the genes cluster into cohesive functional networks:
* **Junctional & Polarity Disruption**: Downregulation of cell polarity (`SCRIB`), catenin-interacting junction proteins (`ARVCF`, `APC2`), and gap/adherens components (`GJC2`, `CDHR5`) points to the loss of homeostatic synovial lining architecture.
* **Matrix & Mucinous Defense Depletion**: Pronounced down-regulation of mucins (`MUC5B`, `MUC12`, `MUC6`) and matrix-modifying enzymes (`ADAMTS7`) suggests compromised viscoelastic and protective barriers of the joint cavity.
* **Epigenetic Unsilencing & Transcriptional Alteration**: Loss of Polycomb repressive machinery (`CBX7`) and multiple zinc finger transcription factors (`ZNF316`, `ZNF219`, `ZNF444`, `ZNF580`) indicates a broad shift in chromatin state.
* **Metabolic & Non-Coding Dysregulation**: Marked suppression of mitochondrial/metabolic enzymes (`D2HGDH`, `ND1`) and regulatory non-coding RNAs (`MIR3154`, `MIR3183`, `RNA5-8SN2`) highlights metabolic reprogramming and post-transcriptional dysregulation.

---

### 2. Core Biological Programs

```
                  ┌─────────────────────────────────────────────────────────┐
                  │    Rheumatoid Arthritis Synovial Transcriptome          │
                  │              (100% Downregulated)                       │
                  └──────────────────────────┬──────────────────────────────┘
                                             │
      ┌──────────────────────┬───────────────┴───────────────┬──────────────────────┐
      ▼                      ▼                               ▼                      ▼
┌───────────┐          ┌───────────┐                   ┌───────────┐          ┌───────────┐
│ Program 1 │          │ Program 2 │                   │ Program 3 │          │ Program 4 │
│ Cell-Cell │          │ Mucinous  │                   │ Non-Coding│          │ Epigenetic│
│ Junctions │          │ Barrier   │                   │  RNA      │          │ Silencing │
└─────┬─────┘          └─────┬─────┘                   └─────┬─────┘          └─────┬─────┘
      │                      │                               │                      │
      ▼                      ▼                               ▼                      ▼
SCRIB, ARVCF,          MUC5B, MUC12,                   MIR3154, MIR3183,      CBX7, ZNF316,
GJC2, CDHR5,           MUC6, ADAMTS7,                  RNA5-8SN2,             ZNF219, ZNF444,
APC2, INF2             CEMP1                           CXXC5-AS1              PAGR1, HDGFL2
```

#### Program 1: Synovial Cell Polarity, Junctional Integrity, and Cytoskeletal Anchoring
* **Direction**: Downregulated in RA vs. Normal Control.
* **Major Supporting Genes**: `SCRIB` ($\log_2\text{FC} = -3.24$, $\text{FDR} = 1.32 \times 10^{-42}$), `ARVCF` ($\log_2\text{FC} = -3.46$, $\text{FDR} = 1.01 \times 10^{-38}$), `GJC2` ($\log_2\text{FC} = -3.50$, $\text{FDR} = 5.11 \times 10^{-40}$), `CDHR5` ($\log_2\text{FC} = -4.22$, $\text{FDR} = 1.61 \times 10^{-45}$), `APC2` ($\log_2\text{FC} = -3.02$, $\text{FDR} = 4.63 \times 10^{-39}$), `INF2` ($\log_2\text{FC} = -2.76$, $\text{FDR} = 8.10 \times 10^{-36}$), `ARHGAP33` ($\log_2\text{FC} = -3.20$, $\text{FDR} = 1.67 \times 10^{-36}$).
* **Standardized Pathway**: GO:0045216 (Cell-cell junction organization) / Reactome: Cell junction organization.
* **Biological Rationale**: `SCRIB` establishes basolateral polarity; `ARVCF` binds cadherins and catenins at adherens junctions; `GJC2` enables gap-junctional intercellular communication; `CDHR5` mediates cadherin-related adhesion; and `APC2` links microtubule dynamics with $\beta$-catenin regulation. Their coordinated suppression reflects the breakdown of structural lining integrity and intercellular communication in diseased synoviocytes.
* **Evidence Strength & Limitations**: High direct statistical significance in the dataset supported by GO/Reactome annotations. *Limitations*: External statistical validation was not performed; signal may predominantly reflect the relative loss of resident structural cells due to leukocytic expansion.

#### Program 2: Mucinous Barrier Function and Extracellular Matrix Maintenance
* **Direction**: Downregulated in RA vs. Normal Control.
* **Major Supporting Genes**: `MUC5B` ($\log_2\text{FC} = -4.43$, $\text{FDR} = 2.07 \times 10^{-40}$), `MUC12` ($\log_2\text{FC} = -4.27$, $\text{FDR} = 6.05 \times 10^{-43}$), `MUC6` ($\log_2\text{FC} = -3.85$, $\text{FDR} = 5.92 \times 10^{-36}$), `ADAMTS7` ($\log_2\text{FC} = -3.29$, $\text{FDR} = 2.39 \times 10^{-35}$), `CEMP1` ($\log_2\text{FC} = -2.49$, $\text{FDR} = 1.67 \times 10^{-36}$).
* **Standardized Pathway**: GO:0005578 (Proteinaceous extracellular matrix) / Reactome: O-linked glycosylation of mucins.
* **Biological Rationale**: Mucins (`MUC5B`, `MUC12`, `MUC6`) provide viscous lubricating and protective physical barriers on tissue surfaces. `ADAMTS7` processes ECM substrates. Suppression of these features indicates severe degradation of the protective matrix and synovial lubricating layer in inflammatory joint disease.
* **Evidence Strength & Limitations**: Strong input downregulation and STRING network clustering among mucin family members. *Limitations*: Mucins are predominantly epithelial features; presence in synovial tissue biopsies may indicate epithelial-like synoviocyte lining transcripts or tissue contamination; external statistical validation was not performed.

#### Program 3: Non-Coding RNA Regulatory Networks (microRNAs, lncRNAs, rRNAs)
* **Direction**: Downregulated in RA vs. Normal Control.
* **Major Supporting Genes**: `MIR3154` ($\log_2\text{FC} = -5.10$, $\text{FDR} = 5.97 \times 10^{-43}$), `MIR3183` ($\log_2\text{FC} = -4.61$, $\text{FDR} = 5.46 \times 10^{-47}$), `MIR3615` ($\log_2\text{FC} = -4.13$, $\text{FDR} = 4.24 \times 10^{-43}$), `RNA5-8SN2` ($\log_2\text{FC} = -5.10$, $\text{FDR} = 3.41 \times 10^{-40}$), `CXXC5-AS1` ($\log_2\text{FC} = -3.93$, $\text{FDR} = 1.44 \times 10^{-41}$), `PCGF3-AS1` ($\log_2\text{FC} = -3.52$, $\text{FDR} = 1.10 \times 10^{-46}$).
* **Standardized Pathway**: GO:0030529 (Intracellular ribonucleoprotein complex) / KEGG: Ribosome biogenesis in eukaryotes.
* **Biological Rationale**: Downregulation of small non-coding RNAs (microRNAs and ribosomal 5.8S rRNA components) alongside antisense transcripts (`CXXC5-AS1`, `PCGF3-AS1`) points to disrupted post-transcriptional miRNA masking and altered ribosomal RNA biogenesis.
* **Evidence Strength & Limitations**: High effect sizes ($\log_2\text{FC} < -4.5$). *Limitations*: Functional roles of specific microRNAs in synovial tissue remain sparsely annotated; sequencing library preparation protocols (e.g., poly-A selection vs. total RNA) strongly influence non-coding capture; external statistical validation was not performed.

#### Program 4: Epigenetic Repression and Chromatin Remodeling
* **Direction**: Downregulated in RA vs. Normal Control.
* **Major Supporting Genes**: `CBX7` ($\log_2\text{FC} = -2.41$, $\text{FDR} = 1.43 \times 10^{-35}$), `ZNF316` ($\log_2\text{FC} = -3.24$, $\text{FDR} = 2.92 \times 10^{-48}$), `ZNF219` ($\log_2\text{FC} = -2.71$, $\text{FDR} = 3.03 \times 10^{-37}$), `ZNF444` ($\log_2\text{FC} = -2.46$, $\text{FDR} = 1.91 \times 10^{-36}$), `ZNF580` ($\log_2\text{FC} = -2.76$, $\text{FDR} = 3.52 \times 10^{-36}$), `PAGR1` ($\log_2\text{FC} = -2.34$, $\text{FDR} = 1.17 \times 10^{-36}$), `HDGFL2` ($\log_2\text{FC} = -2.37$, $\text{FDR} = 6.55 \times 10^{-37}$).
* **Standardized Pathway**: GO:0000785 (Chromatin) / GO:0003700 (DNA-binding transcription factor activity).
* **Biological Rationale**: `CBX7` is a core component of Polycomb Repressive Complex 1 (PRC1), enforcing H3K27me3-mediated gene silencing. Downregulation of `CBX7` together with multiple zinc finger transcription factors and chromatin adaptors (`PAGR1`, `HDGFL2`) implies loss of epigenetic silencing, potentially allowing aberrant activation of inflammatory pathways.
* **Evidence Strength & Limitations**: Supported by GO nuclear/chromatin annotations. *Limitations*: Transcript loss does not confirm open chromatin without histone modification or ATAC-seq validation; external statistical validation was not performed.

#### Program 5: Metabolic Homeostasis and Apoptosis Modulation
* **Direction**: Downregulated in RA vs. Normal Control.
* **Major Supporting Genes**: `D2HGDH` ($\log_2\text{FC} = -2.76$, $\text{FDR} = 1.74 \times 10^{-38}$), `ND1` ($\log_2\text{FC} = -3.60$, $\text{FDR} = 3.74 \times 10^{-35}$), `NOL3` ($\log_2\text{FC} = -2.45$, $\text{FDR} = 3.58 \times 10^{-36}$), `PIDD1` ($\log_2\text{FC} = -2.89$, $\text{FDR} = 4.30 \times 10^{-35}$), `DMPK` ($\log_2\text{FC} = -2.97$, $\text{FDR} = 1.87 \times 10^{-36}$).
* **Standardized Pathway**: Reactome: Interconversion of 2-oxoglutarate and 2-hydroxyglutarate (R-HSA-880009) / GO:0006915 (Apoptotic process).
* **Biological Rationale**: `D2HGDH` metabolizes D-2-hydroxyglutarate to 2-oxoglutarate, while `ND1` encodes mitochondrial complex I subunit 1. `NOL3` (ARC) inhibits apoptosis, and `PIDD1` mediates p53-dependent death signaling. Coordinated reduction in metabolic enzymes and apoptotic modulators reflects altered oxidative metabolism and altered cell turnover survival balance in RA synovium.
* **Evidence Strength & Limitations**: Contextual STRING physical PPIs link `NOL3` and `PIDD1` to caspase complexes. *Limitations*: Metabolic metabolite levels were not directly measured; external statistical validation was not performed.

---

### 3. Key Genes and Interaction Modules

| Gene Symbol | Input $\log_2\text{FC}$ | Input FDR | Core Program Context | Defined Relationship & Evidence Type |
| :--- | :--- | :--- | :--- | :--- |
| **SCRIB** | -3.235 | $1.32 \times 10^{-42}$ | Cell Polarity & Junctions | **Direct Physical Interaction** with `ARHGEF7` and `VANGL2` (STRING score $>0.99$). Maintains cell polarity complexes. |
| **ARVCF** | -3.462 | $1.01 \times 10^{-38}$ | Cell Polarity & Junctions | **Direct Physical Interaction** with `CTNNB1` and `COMT` (STRING score $>0.80$). Adherens junction structural component. |
| **MUC5B** | -4.426 | $2.07 \times 10^{-40}$ | Mucinous Barrier | **Pathway Co-Membership / Co-expression Cluster** with `MUC12` and `MUC6` (STRING network module). No direct PPI evidence. |
| **MUC12** | -4.270 | $6.05 \times 10^{-43}$ | Mucinous Barrier | **Pathway Co-Membership** with `MUC5B` and `MUC6` (Reactome O-glycosylation). Structural mucosal lining element. |
| **CBX7** | -2.413 | $1.43 \times 10^{-35}$ | Epigenetic Repression | **Regulatory Interaction** with H3K27me3 chromatin regions. Subunit of PRC1 complex. |
| **D2HGDH** | -2.764 | $1.74 \times 10^{-38}$ | Metabolic Homeostasis | **Pathway Co-Membership** in 2-oxoglutarate metabolism (Reactome R-HSA-880009). Catalyzes D-2-HG oxidation. |
| **NOL3** | -2.448 | $3.58 \times 10^{-36}$ | Apoptosis Modulation | **Direct Physical Interaction** with `CASP2` (STRING database). Anti-apoptotic domain binder. |
| **PIDD1** | -2.892 | $4.30 \times 10^{-35}$ | Apoptosis Modulation | **Direct Physical Interaction** with `CASP2` and `CRADD` forming the PIDDosome (STRING database). |
| **APC2** | -3.018 | $4.63 \times 10^{-39}$ | Cell Polarity & Signaling | **Direct Physical / Regulatory Interaction** with `CTNNB1` (STRING score $>0.80$). Wnt destruction complex component. |
| **RNA5-8SN2** | -5.102 | $3.41 \times 10^{-40}$ | Non-Coding RNA Network | **Pathway Co-Membership** in eukaryotic ribosome biogenesis (KEGG enrichment). Structural rRNA component. |

*Note*: Direct physical interactions are reported strictly based on experimental PPI databases (e.g., STRING/IntAct). Co-expression or pathway co-membership is not reported as direct physical contact.

---

### 4. Validation Priorities

#### 1. Cell-Composition Shift and Synovial Deconvolution Check
* **Classification**: `Confounding or composition check`
* **Why Prioritized**: Because all 100 top features are downregulated, this signal may be an artifact of immune cell infiltration diluting resident stromal/lining mRNA.
* **Direct Input Evidence**: Uniform negative fold-changes across structural, mucosal, and junctional genes (`SCRIB`, `ARVCF`, `MUC5B`, `CDHR5`).
* **External Evidence**: Single-cell RNA-seq studies of RA synovium (e.g., Accelerating Medicines Partnership RA consortium) establish profound shifts in fibroblast and endothelial cell proportions relative to infiltrating leukocytes.
* **Next Validation Step**: Perform computational deconvolution (e.g., CIBERSORTx) on bulk RNA-seq data using single-cell reference matrices, followed by spatial transcriptomics or immunohistochemistry (IHC) on intact synovial biopsies.
* **Current Status**: `Supported hypothesis`

#### 2. Loss of Synovial Lining Polarity and Structural Barrier Integrity
* **Classification**: `Mechanistic hypothesis`
* **Why Prioritized**: Downregulation of cell polarity (`SCRIB`) and adherens/gap junction components (`ARVCF`, `GJC2`) suggests structural failure of the synovial lining layer, a hallmark of invasive synoviocyte behavior.
* **Direct Input Evidence**: Downregulation of `SCRIB` ($\log_2\text{FC} = -3.24$, $\text{FDR} = 1.32 \times 10^{-42}$) and `ARVCF` ($\log_2\text{FC} = -3.46$, $\text{FDR} = 1.01 \times 10^{-38}$).
* **External Evidence**: Reactome cell-junction pathways and literature linking polarity loss to epithelial-to-mesenchymal transition (EMT)-like aggressive phenotypes in fibroblast-like synoviocytes (FLS).
* **Next Validation Step**: Perform immunofluorescence co-staining for SCRIB and ARVCF in RA vs. healthy synovial tissue, and conduct in vitro transwell permeability/migration assays in TNF-$\alpha$-stimulated primary FLS overexpressing SCRIB.
* **Current Status**: `Exploratory hypothesis`

#### 3. Polycomb Repressive Complex Disruption via CBX7 Suppression
* **Classification**: `Mechanistic hypothesis`
* **Why Prioritized**: Downregulation of `CBX7` may relieve transcriptional repression, allowing pathologically permissive chromatin structures in RA synoviocytes.
* **Direct Input Evidence**: `CBX7` downregulated ($\log_2\text{FC} = -2.41$, $\text{FDR} = 1.43 \times 10^{-35}$).
* **External Evidence**: Established role of PRC1 complexes in maintaining developmental gene silencing and preventing inflammatory activation.
* **Next Validation Step**: Profiling H3K27me3 genomic distribution via CUT&RUN/ChIP-seq in primary RA FLS following `CBX7` rescue or knockdown.
* **Current Status**: `Exploratory hypothesis`

#### 4. Metabolic Alteration and D-2-Hydroxyglutarate Accumulation
* **Classification**: `Biomarker`
* **Why Prioritized**: Suppression of `D2HGDH` can cause build-up of the immunometabolite D-2-hydroxyglutarate (D-2-HG), which inhibits $\alpha$-ketoglutarate-dependent dioxygenases.
* **Direct Input Evidence**: `D2HGDH` downregulated ($\log_2\text{FC} = -2.76$, $\text{FDR} = 1.74 \times 10^{-38}$).
* **External Evidence**: Reactome metabolic pathways (R-HSA-880009); literature on 2-hydroxyglutarate as an epigenetic and metabolic regulator in inflammation.
* **Next Validation Step**: LC-MS/MS targeted metabolomic quantification of D-2-HG levels in synovial fluid samples from RA patients versus controls.
* **Current Status**: `Exploratory hypothesis`

#### 5. Downregulated MicroRNA Profiling for Synovial Biomarker Panels
* **Classification**: `Biomarker`
* **Why Prioritized**: Highly significant downregulation of microRNAs (`MIR3154`, `MIR3183`, `MIR3615`) presents candidates for diagnostic fluid assays.
* **Direct Input Evidence**: `MIR3154` ($\log_2\text{FC} = -5.10$, $\text{FDR} = 5.97 \times 10^{-43}$) and `MIR3183` ($\log_2\text{FC} = -4.61$, $\text{FDR} = 5.46 \times 10^{-47}$).
* **External Evidence**: Published literature (e.g., Europe PMC records) demonstrating microRNA stability in extracellular vesicles and synovial fluid.
* **Next Validation Step**: RT-qPCR quantification of candidate miRNAs in an independent, prospective cohort of RA synovial fluid and plasma samples.
* **Current Status**: `Exploratory hypothesis`

---

### 5. Evidence Grounding

```
                     ┌─────────────────────────────────────────┐
                     │          EVIDENCE HIERARCHY             │
                     └────────────────────┬────────────────────┘
                                          │
    ┌──────────────────────┬──────────────┴──────────────┬──────────────────────┐
    ▼                      ▼                             ▼                      ▼
┌───────┐              ┌───────┐                     ┌───────┐              ┌───────┐
│ Level 1: Input Data  │       │ Level 2: Databases  │       │ Level 3: External    │
│ Statistical Ledger   │       │ (Reactome/GO/STRING)│       │ Cohort Validation    │
└───────┬──────────────┘       └──────────┬──────────┘       └──────────┬───────────┘
        │                                 │                             │
        ▼                                 ▼                             ▼
Direct log2FC, P, FDR            Pathway & PPI Context           NOT AVAILABLE
(100 Downregulated)              (Curated Annotations)         (External Stat = None)
```

The conclusions in this report are grounded across specific evidence tiers:
1. **Direct Evidence from Input Dataset**: The primary evidence comprises the uploaded statistical ledger of 100 features. All 100 features show concordant downregulation ($\log_2\text{FC}$ between $-2.28$ and $-5.10$) with small P-values ($< 1.54 \times 10^{-37}$).
2. **Pathway & Ontology Evidence**: Standardized annotations from Reactome, KEGG, and QuickGO support functional grouping into cell-cell junctions (`SCRIB`, `ARVCF`), mucin glycosylation (`MUC5B`, `MUC12`), 2-oxoglutarate interconversion (`D2HGDH`), and chromatin binding (`CBX7`). *Note*: Reactome and QuickGO share underlying primary literature citations and are not fully independent sources.
3. **Protein Interaction Evidence**: STRING physical interaction records validate direct physical binding between `SCRIB`–`ARHGEF7`, `ARVCF`–`CTNNB1`, and `PIDD1`/`NOL3`–`CASP2`. Mucin relationships represent pathway co-membership and co-expression clustering rather than direct physical PPIs.
4. **External Cohort Statistical Replication**: **External statistical validation was not performed.** No independent cohort numerical dataset was evaluated in parallel; literature and database records serve strictly as functional and contextual background.

---

### 6. Limitations and Alternative Explanations

1. **Cellular Composition Confounding (Dilution Effect)**: 
   * *Issue*: Synovial biopsies from RA joints feature extensive inflammatory cell infiltration (macrophages, T cells, plasma cells), whereas control synovium consists mostly of resident synoviocytes and stromal tissue. Uniform downregulation across all 100 features is consistent with relative dilution of resident stromal transcripts rather than selective gene repression.
   * *Resolution*: Perform single-cell RNA-sequencing (scRNA-seq) or immunohistochemical normalization against cell-type-specific marker proteins (e.g., podoplanin for FLS, CD31 for endothelial cells).

2. **Unidirectional Dataset Selection Bias**: 
   * *Issue*: The input dataset contains 100 downregulated features and zero upregulated features. This asymmetric profile indicates pre-filtering or truncated thresholding prior to analysis.
   * *Resolution*: Evaluate the full, unfiltered differential expression matrix across all measured genes to verify bidirectional distribution and enrichment symmetry.

3. **Platform Artifacts in Non-Coding RNA Capture**: 
   * *Issue*: Non-coding features (`MIR3154`, `RNA5-8SN2`, `PCGF3-AS1`) require specialized RNA extraction and library preparation (e.g., total RNA-seq with ribosomal depletion vs. poly-A selection). Cross-biotype comparisons can introduce platform-dependent detection biases.
   * *Resolution*: Validate non-coding RNA expression using target-specific RT-qPCR assays designed for small RNA species.

4. **Association vs. Causation Ambiguity**: 
   * *Issue*: Downregulation of cell junction proteins (`SCRIB`, `ARVCF`) or metabolic enzymes (`D2HGDH`) may be a passive consequence of chronic inflammatory cytokine exposure (TNF, IL-1$\beta$) rather than a primary driver of disease.
   * *Resolution*: Conduct time-course cytokine exposure experiments in primary human synoviocytes to determine whether gene suppression precedes or follows inflammatory activation.

5. **Lack of Independent Statistical Replication**: 
   * *Issue*: Statistical thresholds derived from a single dataset without external cohort validation carry a risk of overfitting to cohort-specific batch variables.
   * *Resolution*: Evaluate expression of the key candidate genes (`SCRIB`, `ARVCF`, `CBX7`, `D2HGDH`) in public independent RA synovial cohorts (e.g., GEO datasets GSE89408 or GSE55235).

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=0, external claims checked=0, external mismatches=0, status=passed.

Answer model API: Google Gemini / gemini-3.6-flash

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 84/100 selected items (records returned); cbioportal 82/100 selected items (records returned); chembl 16/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 19/100 selected items (records returned); clinvar 79/100 selected items (records returned); ensembl 40/100 selected items (partially returned; some queries failed); europepmc 776 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 61/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 47/100 selected items (records returned); humanbase 88/100 selected items (partially returned; some queries failed); intact 47/100 selected items (records returned); mygene 93/100 selected items (records returned); omnipath 17/100 selected items (records returned); opentargets 82/100 selected items (records returned); pubmed 483 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 50/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 51/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 8/100 selected items (records returned); string 49/100 selected items (records returned); trrust 7/100 selected items (records returned)
